600216 浙江医药
2026/06 - 中期
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额452,2501,885,7691,223,299634,311520,603
投资活动产生之现金流量净额(720,122)(371,947)(473,500)(518,591)(971,154)
筹资活动产生之现金流量净额514,422(402,863)(255,321)(141,430)43,914
汇率变动对现金及现金等价物的影响(48,740)90,28711,26847,64076,015
现金及现金等价物净增加/(减少)197,8101,201,247505,74621,930(330,622)
期初现金及现金等价物余额3,166,8321,965,5851,459,8401,437,9091,768,532
期末现金及现金等价物余额3,364,6423,166,8321,965,5851,459,8401,437,909